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Abstract
Germline mutations of the Liver Kinase b1 (LKB1/STK11) tumor suppressor gene have been linked to Peutz-Jeghers
Syndrome (PJS), an autosomal-dominant, cancer-prone disorder in which patients develop neoplasms in several organs,
including the oviduct, ovary, and cervix. We have conditionally deleted Lkb1 in Mu ¨llerian duct mesenchyme-derived cells of
the female reproductive tract and observed expansion of the stromal compartment and hyperplasia and/or neoplasia of
adjacent epithelial cells throughout the reproductive tract with paratubal cysts and adenomyomas in oviducts and,
eventually, endometrial cancer. Examination of the proliferation marker phospho-histone H3 and mammalian Target Of
Rapamycin Complex 1 (mTORC1) pathway members revealed increased proliferation and mTORC1 activation in stromal cells
of both the oviduct and uterus. Treatment with rapamycin, an inhibitor of mTORC1 activity, decreased tumor burden in
adult Lkb1 mutant mice. Deletion of the genes for Tuberous Sclerosis 1 (Tsc1)o rTsc2, regulators of mTORC1 that are
downstream of LKB1 signaling, in the oviductal and uterine stroma phenocopies some of the defects observed in Lkb1
mutant mice, confirming that dysregulated mTORC1 activation in the Lkb1-deleted stroma contributes to the phenotype.
Loss of PTEN, an upstream regulator of mTORC1 signaling, along with Lkb1 deletion significantly increased tumor burden in
uteri and induced tumorigenesis in the cervix and vagina. These studies show that LKB1/TSC1/TSC2/mTORC1 signaling in
mesenchymal cells is important for the maintenance of epithelial integrity and suppression of carcinogenesis in adjacent
epithelial cells. Because similar changes in the stromal population are also observed in human oviductal/ovarian adenoma
and endometrial adenocarcinoma patients, we predict that dysregulated mTORC1 activity by upstream mechanisms similar
to those described in these model systems contributes to the pathogenesis of these human diseases.
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Introduction
The embryonic Mu ¨llerian ducts, which are composed of a
simple columnar epithelium surrounded by mesenchymal cells,
differentiate into the oviducts, uterus, cervix, and anterior portion
of the vagina [1]. During differentiation, epithelial-mesenchymal
communication plays an important role in specification of the
Mu ¨llerian duct epithelium into ciliated and secretory (oviduct),
columnar (uterus), and squamous (cervix) epithelium [2]. Confir-
mation of the control exerted by the stroma on differentiation,
shown using tissue recombination studies mixing uterine or vaginal
stroma and epithelia, have revealed that the fate of epithelial cells
depends on stromal/mesenchymal signaling [2,3]. In the uterus,
epithelial-mesenchymal crosstalk also plays an important role in
development of epithelial cancer. For example, in our recent
study, we showed that conditional deletion of Adenomatous
Polyposis Coli (APC) in endometrial stromal cells results in their
conversion to a myofibroblast phenotype, which was sufficient to
initiate endometrial hyperplasia that could lead to endometrial
cancer in mice [4]. The physiological relevance of the endometrial
stroma cell conversion was confirmed when a myofibroblast
stromal phenotype was also observed in human endometrial
epithelial cancer patient tissue samples [4].
Peutz-Jeghers syndrome (PJS) is a hereditary cancer-prone
disorder linked to mutation of LKB1 (also known as Serine/
Threonine Protein Kinase 11; STK11) [5]. Patients with PJS are at
high risk of developing cancerous lesions in various organs
including testis, ovary, endocervix, breast, and colon [6]. LKB1
encodes an evolutionarily conserved serine/threonine kinase that
phosphorylates and activates a family of related AMP kinases
(AMPK) in response to a decline in the cellular ATP:AMP ratio,
acting as a metabolic rheostat to maintain energy homeostasis [7].
One of the best studied targets of AMPK is mammalian target
of rapamycin complex 1 (mTORC1), a master regulator of
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TSC1/TSC2 tumor suppressor complex and directly by phos-
phorylation of regulator-associated protein of mTOR (Raptor), a
substrate binding component of the rapamycin-sensitive
mTORC1 [5]. LKB1-AMPK tumor suppressor activity has also
been associated with another of its major functions, controlling cell
polarity, which appears to be the central mechanism suppressing
tumorigenesis in a pancreatic cancer model with loss of LKB1 [8].
Adenoviral-delivered Cre-mediated deletion of Lkb1 in murine
endometrial epithelium can drive development of highly invasive
endometrial adenocarcinoma [9] showing that LKB1 is an
important tumor suppressor in endometrial carcinogenesis.
Mutations in LKB1 are also detected in human cervical cancer
patients, and PJS patients also develop endocervical cancer known
as adenoma malignum/minimum deviation of adenocarcinoma
[10]. Although most reports of tumorigenesis are from mutated
epithelial cells, loss of LKB1 in mesenchymal cells using Smooth
Muscle 22-cre has been shown to lead to the development of
polyps with features similar to those found in PJS patients [11]. Of
note, gastrointestinal polyps from PJS patients contain more
myofibroblastic stromal cells, which is similar to the phenotype
mice develop after deletion of endometrial stromal APC [4].
LKB1 is highly expressed in the mesenchymal cells of human
gonads and patients with PJS develop ovarian and testicular
stromal tumors [12–14], suggesting that LKB1 might be an
important tumor suppressor in the stromal cells of reproductive
organs. This hypothesis is supported by the recent findings that,
whereas, heterozygous deletion of LKB1 in both epithelium and
stroma results in endometrial cancer [9], heterozygosity of LKB1
in the epithelium alone does not [15].
In order to investigate whether deletion of LKB1 from
reproductive tract and gonadal stromal cells leads to the
gynecological abnormalities observed in PJS patients, we gener-
ated mice with conditional deletion of LKB1 in the stromal cells of
the female reproductive tract using Mu ¨llerian inhibiting substance
receptor 2-driven Cre (Misr2-Cre) [16]. A significant proportion of
PJS patients harbor mutations that encompass whole or partial
LKB1 gene deletions, make this mouse model appropriate for
studying this disease. We observed expansion of the myofibroblast
population accompanied by hyperplasia and/or neoplasia of the
epithelia of both oviduct and uterus. Loss of TSC1 or TSC2 using
the same Cre is able to phenocopy some of the reproductive
pathologies of Lkb1-deleted mice, suggesting that their common
downstream target, mTORC1, plays a role in their pathogenesis
when dysregulated. These results show the importance of
mesenchymal LKB1/TSC1/TSC2/mTORC1 signaling in the
female reproductive tract and provide a compelling rationale for
considering the therapeutic option of mTORC1 inhibitors for
these patients.
Results
Women with PJS are prone to developing multiple gynecolog-
ical pathologies including oviductal and uterine cancers [5,6,17]
and minimal deviation adenocarcinoma/adenoma malignum of
uterine cervix [18]. While these latter tumors are malignant in
nature, histologically they appear as benign tumors because of the
significant amount of stroma and sparsely placed, normal looking
epithelial glands [18]. However, the pathogenesis of female
reproductive tract abnormities and the mechanisms disrupted by
mutant LKB1 are still unclear. In this study, we have developed
conditional deletion of exon 3–6 of the Lkb1 gene in the Mu ¨llerian
duct mesenchyme-derived stromal cells of the murine female
reproductive tract by crossing Mu ¨llerian inhibiting substance type
2 receptor-drive Cre (Misr2-Cre, also known as antiMu ¨llerian
hormone type 2 receptor Amhr2-Cre) [16] mice with Lkb1
fl/fl [19]
mice to develop Lkb1
cko mice to determine whether the loss of
LKB1 affects either female reproductive development or results in
PJS-associated pathologies. Previous studies have successfully used
Misr2-Cre to induce recombination in mesenchymal cells of the
female reproductive tract [4,20–23]. To confirm that Misr2-Cre
expression is limited to the mesenchymal cells of the female
reproductive tract, we used the Rosa26-Lacz Cre reporter strain in
which b-galactosidase is expressed in cells also expressing Misr2-
Cre and showed that, in the oviducts, cervix and vagina, b-
galactosidase activity is limited to the stromal cells (Figure S1A). In
the uterus, b-galactosidase activity is confined to the mesenchymal
cells as previously described [4]. Genomic PCR confirms that
recombination of the Lkb1 flox allele occurs in the reproductive
tract tissues of mutant mice (Figure S1D).
Abnormal expansion of the stromal compartment in
Lkb1
cko oviducts
No gross defects were observed in 5 week old control and Lkb1
cko
mutant (N=3/each) oviducts (Figure 1A and 1B). After 18 weeks,
grossly visible cystic growths of various sizes were observed in the
oviducts of mutant females (N=5/5; Figure 1D). Normal oviduct
development was observed in age-matched control littermates
(N=5/5; Figure 1C). Initial examination of ovaries from both
groups of mice revealed the presence of corpora lutea, suggesting
normal ovulation and ovarian functions (data not shown).
Histological examination of the control and mutant oviducts
was performed to evaluate cellular changes after loss of LKB1. At
5 weeks of age, H&E-stained sections of mutant oviducts showed
increased thickness of the LKB1-deleted stromal compartment
compared with controls (N=3; Figure 1E–1J). Stromal cells of the
mutant oviducts were also more disorganized compared with age-
matched controls and oviductal epithelial cells of mutant mice had
a more irregular and vacuolated arrangement (Figure 1G–1J) and
were often found occluding the lumen (Figure 1J). Examination of
Author Summary
Peutz-Jeghers Syndrome patients have autosomal domi-
nant mutations in the LKB1/STK11 gene and are prone to
developing cancer, predominantly in the intestinal tract
but also in other tissues, including the reproductive tracts
and gonads. To elucidate the mechanisms disrupted by
the loss of LKB1 in the reproductive tract, we have
developed a mouse model with deletion of Lkb1 specif-
ically in stromal cells of gynecologic tissues. These mice
show stromal cell expansion and develop oviductal
adenomas and endometrial cancer. Deletion of either
Tsc1 or Tsc2 genes, which are mutated in patients with
Tuberous Sclerosis Complex and whose protein products
are indirect downstream targets of LKB1 signaling, resulted
in some of the same defects observed in Lkb1 mutant
mice. Activation of mammalian Target Of Rapamycin
Complex 1 (mTORC1), a common effector of disrupted
LKB1, TSC1, and TSC2 signaling, was observed in all mutant
tissues examined, suggesting that uninhibited mTORC1
activity is necessary for the phenotypes. Suppression of
mTORC1 signaling by rapamycin reduced tumor burden in
Lkb1 mutant mice, confirming the link between dysregu-
lation of mTORC1 to development of the Lkb1 mutant
phenotype and suggesting that therapeutic targeting of
LKB1/TSC1/TSC2/mTORC1 signaling would benefit human
Peutz-Jeghers Syndrome and Tuberous Sclerosis patients
with reproductive tract disease.
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cko mice. Gross examination of 5 week old control (A) and Lkb1
cko mutant (B) mice revealed normal
looking coiled oviducts. Oviducts of 18 week old control (C) and mutant (D) mice show the presence of cysts, which were either large as shown in
Panel D or microscopic (not shown). Histology of 5 week old control (E, and higher magnification of boxed area F) and mutant (G–J) oviducts with
abnormal epithelial and stromal cells. Higher magnification images of oviducts showing abnormal epithelium next to mutant stromal cells (H and J;
arrow); normal looking epithelial cells (I; arrowhead) were present away from the stromal cells. Colocalization of desmin and aSMA in 5 week old
(n=3) control (K–L) and mutant (M–N) oviducts. White arrowheads mark abnormal cell growth in mutant oviducts. Histology of 18 week old control
(O) and mutant (P) oviducts showed greater stromal expansion in the mutants, which was confirmed by co-immunostaining with desmin and aSMA
of adult control (Q) and mutant (R) oviducts. Masson’s Trichrome staining indicates significantly greater collagen deposition (blue) in 18 week old
mutant oviducts (T–V) compared to controls (S). Ovi; oviducts; O; ovary, Ut; uterus. Bars: 50 um.
doi:10.1371/journal.pgen.1002906.g001
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aSmooth Muscle Actin (aSMA) in the 5 week old oviducts by
immunofluorescence confirmed expansion of aSMA+/desmin- or
weakly desmin+ stromal cell population, indicating dysregulated
proliferation of Lkb1-deleted stromal cells (Figure 1M and 1N)
compared with controls (Figure 1K and 1L). A similar expansion
of aSMA+/desmin- myofibroblast cells was also observed in
polyps from human PJS patients and other mouse models with loss
of LKB1 [11]. By 18 weeks, histological examination of mutant
oviducts showed massive expansion of the stromal compartment
compared with controls (Figure 1O and 1P). Co-staining with
aSMA and desmin confirmed the increase in smooth muscle/
myofibroblast cells in the stroma of Lkb1
cko oviducts (Figure 1Q
and 1R).
The extracellular matrix (ECM) plays an important role in
determining epithelial cell integrity and polarity [24]. In the
uterus, stromal cells secrete and deposit various components of
ECM [25], including collagen and laminin, which play an
important role in endometrial remodeling [26]. Additionally,
altered production of ECM components is observed in various
endometrial pathologies [27,28]. For this study, we hypothesized
that expansion of the stromal population in mutant oviducts affects
the production and deposition of ECM components. To test this
we performed Masson’s Trichrome staining of control and mutant
oviducts (N=3/each) and observed a significant increase in blue
staining, indicative of collagen in the stromal compartment of
mutant oviducts (Figure 1U–1V). By comparison, collagen-specific
staining is limited to the basement membrane of the control
oviducts (Figure 1S). Next we examined expression of various
cytoskeleton proteins (cytokeratin, b-catenin, E-cadherin and
Tight Junction Protein-1/Zona Occuldens1 (TJP1/ZO1) to
determine if there were any changes in oviductal epithelial cells
due to the stromal expansion and alterations in ECM (Figure S2).
No differences in the expression of cytokeratin, b-catenin, E-
cadherin, and TJP-1 were observed between attached mutant and
control oviductal epithelial cells. However, their expression did
appear abnormal in detached epithelial cells present in the lumen
of the mutant oviducts.
To confirm that the normal differentiation of the oviductal
epithelial cells was not affected by the changes in the mesenchymal
cells of the mutant oviducts, we perform colocalization of paired
box gene 2 (PAX2) and aSMA in oviducts of both control and
mutant mice (Figure S2). PAX2 is a marker of the murine
reproductive tract epithelial cells and loss of the Pax2 gene is
associated with dysgenesis of reproductive tract [29]. Normally
PAX2 is not expressed in the epithelium of the distal segment of
the mouse oviduct and no changes in the expression pattern of
PAX2 were observed between control and mutant oviducts (Figure
S2).
Abnormal cystic growth and hyperplasia of Lkb1
cko
oviductal epithelium
PJS patients have been diagnosed with cystic growths in their
Fallopian tubes that are either filled with translucent white fluid or
pus (pyosalpinx) [17]. Figure 1D shows a typical large cyst in the
Lkb1
cko oviduct, and histological examination of Lkb1
cko mutant
oviducts revealed numerous smaller cystic growths as well (N=5/
5) (Figure 2). The distended blind cysts in mutant mice were highly
variable in size, often accompanied by stromal expansion
(Figure 2C), and often filled with either bloody or pale fluid
similar to hematosalpinx, and pyosalpinx, respectively (Figure 2D).
We injected bromophenol blue dye into the lumen of mutant and
control oviducts to determine whether the fluid accumulating in
the cysts was derived from the lumen, which in normal oviducts
Figure 2. Hyperplastic and/or cystic growth in oviducts of Lkb1
cko mice. (A and B) Abnormal epithelial growth (arrow) in adult mutant
oviducts. Panel B is a magnified image of the area outlined by a solid rectangle in panel A. Glandular epithelium is present in some parts of the
mutant oviduct (C). Cysts of variable size were observed in adult mutant mice (D–F). Blue dye injections into the oviductal lumen (G and H) and from
the lumen of the uterus (I and J) in control and mutant mice. Arrowhead in panel G marks blue dye in the oviductal lumen. Arrows in Panel H point to
accumulation of dye in oviductal cysts. Arrows in panels I and J are directed to the oviducts. O: ovary, S: stroma, Cy: cyst, Ut: uterus. Bars: 50 um
unless otherwise indicated.
doi:10.1371/journal.pgen.1002906.g002
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accumulation of dye in small cystic growths was observed,
suggesting that the cysts were directly connected to the lumen or
that the oviductal epithelial basement membrane had become
permeable (Figure 2G and 2H). Additionally, when dye was
injected from the uterine side, no dye was observed in the
oviductal lumen of control mice but was observed in the mutant
oviducts (Figure 2I and 2J), suggesting a defective uterotubular
junction in mutants and consistent with loss of control of
retrograde flow [20].
LKB1 plays an important role in various biological processes,
including cell proliferation, by interacting with AMP kinases
(AMPKs) and regulating mTORC1 activation [5]. We therefore
examined expression of phospho-histone H3 (pH 3), a marker for
mitotic cells, to determine the rate of cellular proliferation in
control and mutant oviducts. Increased pH 3-positive cells in both
epithelial (arrow) and stromal (arrowheads) compartments was
observed in mutant oviducts compared to controls (Figure 3A and
3B). Analysis of the expression of phosphorylated forms of mTOR
and riboprotein S6, a target of S6 Kinase that is downstream of
activated mTORC1, showed increased phosphorylation of both
mTOR (Ser2448) and S6 (Ser235/236) in the mesenchymal cells
of the mutant oviducts (Figure 3C–3F). Since phosphorylation of
S6 at Ser235/236 sites is regulated by both mTORC1 and
mitogen-activated protein kinases [30] we confirmed mTORC1
involvement by western blot analyses and showed decreased
expression of pRAPTOR (Ser792) and increased phosphorylation
of S6 (Ser235/236; pS6/S6 ratio: 12.361.9 mutant/8.261.9
control) and eukaryotic translation initiation factor 4E-Binding
Protein 1 (4EBP1, Thr37/46; p4EBP1/4EBP1 ratio: 0.860.0
mutant/0.560.1 control) in the mutant oviducts (n=3)
(Figure 3G). LKB1 has also been shown to affect Wnt signaling,
dysregulation of which causes defects in oviduct development and
differentiation [5,22,31]. We measured b-catenin protein levels in
oviducts by western blot and observed no change in expression of
b-catenin between control and mutant oviducts (Figure 3G),
suggesting that defects observed in Lkb1 mutant oviducts are
independent of canonical Wnt signaling.
LKB1 is also an inhibitor of transforming growth factor b
(TGFb) signaling [32], which can play an important role in
fibroblast differentiation and fibrosis [33] and has been implicated
in carcinogenesis of various organs [4,34,35]. In this study, we
evaluated TGFb signaling and observed an increase in expression
and nuclear translocation of the phosphorylated and active form
(Ser465/467) of its downstream target, SMA and Mothers Against
Decapentaplegic homolog 2 (SMAD2), in mesenchymal cells of
both 5 week-old and adult mutant oviducts compared to controls
(Figure 3H–3O), which was confirmed by western blot analysis
(Figure 3G). Since stromal bone morphogenetic protein (BMP)
signaling also plays a role in regulating the growth of intestinal
epithelium and its inhibition leads to polyposis in mice [36], we
examined and found comparable pSMAD1/5/8 in Lkb1 mutant
and control mice (data not shown), suggesting BMP signaling is not
affected in our model system. These results suggest that stromal
expansion and increased ECM deposition in the mutant oviducts
could both be the result of dysregulated TGFb signaling.
Loss of TSC1 or TSC2 in oviductal stromal cells causes
development of cystic and abnormal growth in mutant
oviducts
Because we observed increased mTORC1 activity in the
stromal cells of Lkb1
cko oviducts (Figure 3), we reasoned that
deletion of other genes involved in the regulation of the mTORC1
pathway would phenocopy the defects observed in Lkb1
cko
oviducts. For example, TSC1 and TSC2 act together as a
complex to modulate the activity of the mTORC1 signaling
pathway and loss of TSC1 or TSC2 leads to hyperactivation of
mTORC1 signaling [37]. To study the effects of TSC1 and TSC2
loss in mesenchymal cells of the oviduct, we developed mice with
conditional deletion of Tsc1 (Tsc1
cko) and Tsc2 (Tsc2
cko) by using the
same Misr2-Cre we used to generate the Lkb1
cko mice. Deletion of
Tsc2 in the female reproductive tract (oviduct, ovary, and uterus)
was confirmed using genomic PCR (Figure S1E). Gross examina-
tion of female reproductive tract revealed no obvious differences
between control and Tsc2
cko mutant mice (data not shown).
However, histological examination of 6 week old oviducts revealed
moderate hyperplasia of epithelial cells in mutants compared with
controls (Figure S3). By 18 weeks, the oviducts of Tsc2
cko mice
showed expansion of both stromal and epithelial compartments
accompanied by abnormal cystic growth (N=5/5) (Figure 4B, 4D,
4F) compared to controls (N=4/4) (Figure 4A, 4C, 4E). Similar to
Lkb1
cko and Tsc2
cko mutants, abnormal cystic lesions were also
observed in the oviducts of the older Tsc1
cko mutant females
(N=3/each) (Figure 4I–4K).
Histological examination of the oviducts from Lkb1
cko, Tsc1
cko and
Tsc2
cko mice also revealed the presence of adenomyomas (Figure 2
and Figure 4), nodular lesions consisting of simple glandular, often
hyperplastic epithelium with abnormal stromal cell expansion as a
prominent feature (Figure 1 and Figure 4). In humans, adenomy-
omas are observed in various organs including the oviduct, ovary,
uterus, and intestine [38–41]. Because we observed development
of adenomyomas in the mutant animals with a significant
myofibroblastic stromal cell population, we hypothesized that
human oviductal/ovarian adenomyomas might also be the result
aberrant stromal cell expansion and conversion to myofibroblasts.
We analyzed expression of aSMA and desmin in normal human
oviducts and oviductal adenomas to study changes in the stromal
compartment (Figure 4L–4O) and found that expression of these
markers was limited to the blood vessels and very little staining was
observed in the stromal cells (Figure 4N). In contrast, aSMA and
desmin staining is increased in the stroma of the oviductal
adenomyomas (N=8/10) (Figure 4O), suggesting of expansion of
myofibroblast/smooth muscle cell population.
Deletion of Lkb1/Tsc2/Tsc1 in the endometrial stromal
compartment is sufficient to initiate uterine epithelial
hyperplasia and neoplasia
The mouse uterus is comprised of three different compartments:
endometrial (luminal and glandular) epithelium, endometrial
stroma, and myometrium (smooth muscle cells) [42]. In our
previous study, we showed that deletion of APC in the stromal
compartment is sufficient to induce endometrial cancer in mice
and also observed comparable changes in human endometrial
cancer patients suggesting that mesenchymal cells play an
important role in the etiology of endometrial cancer [4]. The
LKB1/mTORC1 signaling pathways have also been implicated in
endometrial carcinogenesis [15,43]. We examined uteri from 9
week old control and Lkb1
cko mutant mice and found evidence of
endometrial epithelial hyperplasia and endometrial cancer with
expansion of the myofibroblastic population in the Lkb1
cko mice but
not in the controls (Figure 5A–5D). Colocalization of aSMA and
cytokeratin 8 (CK8; epithelial marker) confirmed expansion of
myofibroblast cell population in the stromal compartment
adjacent to the CK8+ epithelial lining in mutant uteri (Figure 5F
and Figure S4). In contrast, only aSMA-negative stromal cells are
present close to CK8+ epithelial cells in control uteri (Figure 5E).
Examination of the reproductive tracts from older mutant
animals (N=5/5) showed that their uteri were greatly enlarged
Stromal LKB1 Mutation Can Drive Gynecologic Cancer
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the myometrial compartment, which is a hallmark of endometrial
adenocarcinoma [44] (Figure 5H, 5K, 5N). In contrast, control
uteri (N=5/5) were much smaller and epithelial cells were limited
to the endometrial/stromal compartment (Figure 5G, 5J, 5M;
Figure S4A). A previous study showed that approximately 30% of
Figure 3. Activation of mTORC1 and TGFb signaling in the stromal compartment of mutant oviducts. Expression analysis of pH 3, a
marker for proliferation, revealed increased numbers of dividing cells in the stromal (arrowhead) and epithelial (arrow) compartments of mutant
oviducts (B) compared with controls (A). pH 3 staining in antral follicles of the ovary (O) was used as a positive control (A). Phosphorylation of mTOR
(C and D) and S6 (E and F) is increased in the stromal cells of the mutants (D and F). (G) Western blot analyses of pRAPTOR (Ser792), pS6 (Ser235/236),
S6, 4EBP1, p4EBP1 (Thr37/46), b-catenin, pSMAD2 (Ser465/467) oviduct protein extract in mutants and controls. b-actin was used as loading control.
(H–O) pSMAD2 protein expression was also increased in mutant (L, M, N and O) compared to control oviducts (H, I, J and K). Bars: 50 um.
doi:10.1371/journal.pgen.1002906.g003
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PLOS Genetics | www.plosgenetics.org 6 August 2012 | Volume 8 | Issue 8 | e1002906Figure 4. Conditional deletion of Tsc1 or Tsc2 phenocopies some of the changes observed in LKB1
cko oviducts. H&E stained adult control
(A, C and E) and Tsc2
cko mutant (B, D and F) oviducts. Panel C to F are high magnification images of rectangular areas mark with dotted line in Panel A
and B. (G and H) Histology of control oviducts. (I–K) Abnormal growth containing epithelial glands and stroma in oviducts of older Tsc1
cko mice.
Panels J and K are higher magnification images of areas outlined by solid rectangles in Panel I. Oviducts from normal human (L) and patients with
adenomas (M). Increased numbers of desmin- and aSMA-positive cells in the stromal compartment in oviductal adenoma patients (O) compared to
normal oviducts (N). O: ovary; Ut: uterus. Bars: 50 um unless otherwise indicated.
doi:10.1371/journal.pgen.1002906.g004
Stromal LKB1 Mutation Can Drive Gynecologic Cancer
PLOS Genetics | www.plosgenetics.org 7 August 2012 | Volume 8 | Issue 8 | e1002906Lkb1+/2 mice developed endometrial cancer and that biallelic
uterine epithelial specific loss of Lkb1 using adenoviral Cre was
sufficient to induce highly invasive endometrial adenocarcinoma
[9]. To compare tumorigenesis in mice with stromal Lkb1
cko
alone with mice with epithelial loss of Lkb1, we generated
another mouse (Lkb1
cko/-) in which one allele of Lkb1 is deleted in
all cells, including the epithelial cells of the uterus, and the other
allele is floxed only in the Mu ¨llerian duct mesenchyme-derived
stromal cells (Figure 5I, 5L, 5O; Figure S4C). Comparison of
endometrial cancer formed in Lkb1
cko and Lkb1
cko/- using aSMA
and CK8 immunostaining revealed that tumors in both model
systems were very similar (Figure 5N and 5O). Particularly
noteworthy was the increased aSMA+ cell population adjacent
to CK8+ cells observed in both models (Figure 5N and 5O)
compared with controls. However, tumors formed in Lkb1
cko/-
were bigger, more aggressive and invasive compared to Lkb1
cko
mice, supporting the findings of the previous report [9] and
showing the importance of epithelial LKB1 loss to endometrial
carcinogenesis. Similar to Lkb1
cko oviducts (Figure 3), we
observed increased proliferation of uterine mesenchymal cells
as confirmed by pH 3 staining in Lkb1
cko mutants compared with
controls (Figure S4F and S4G).
Figure 5. Loss of LKB1 in mesenchymal cells induces endometrial cancer. H&E-stained sections of 9 week old control (A and C) and Lkb1
cko
mutant (B and D) uteri. Immunostaining for CK8 (green) and aSMA (red) of 9 week old control (E) and Lkb1
cko (F) uteri. Histology and CK8/aSMA
immunostaining of 6 month old Lkb1
fl/fl (G, J and M), Lkb1
cko (H, K and N), Lkb1
cko/- (I, L and O). Arrowheads in panels H, I, K, L point to invasive
glandular epithelium present in the myometrial compartment, a hallmark of endometrial adenocarcinoma. E: epithelium, M: myometrium, S: stroma.
Bars: 50 um.
doi:10.1371/journal.pgen.1002906.g005
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revealed increased mTORC1 and TGFb signaling activity in
Lkb1
cko uteri compared to controls (Figure S4H–S4M). Because we
observed increased mTORC1 activity in Lkb1
cko uteri, we treated
aged Lkb1
cko mice (.7 month old) with rapamycin or vehicle
(N=3/group) as previously described [45]. After 3 weeks of
treatment, we observed decreased uterine weight accompanied by
reduced expression of pS6 in rapamycin-treated mice compared
with controls (Figure 6A–6E). Histological examination of
rapamycin- and vehicle-treated uteri and oviducts showed
suppression of endometrial carcinogenesis (Figure 6F and 6G)
and inhibition of cyst formation (Figure S5A), respectively, with
rapamycin treatment confirming the involvement of mTORC1 in
the pathogenesis of the Lkb1 mutant phenotype.
We also analyzed uteri from Tsc1
cko and Tsc2
cko mice to
determine whether deletion of these upstream regulators of
mTORC1 activity resulted in phenotypes similar to those
observed in the Lkb1
cko uteri. Compared to controls, Tsc2
cko and
Tsc1
cko uteri were enlarged and showed hyperplasia or neoplasia of
the endometrial epithelium (Figure 6H–6J). Immunolocalization of
aSMA and CK8 revealed that, similar to Lkb1 mutant uteri,
Tsc2
cko and Tsc1
cko uteri showed expansion of the aSMA+ and
CK8+ cell populations (Figure 6K–6M). In contrast to Lkb1
cko or
Lkb1
cko/- endometrial cancers, myometrial invasion of epithelial
cells (Figure 6L and 6M) and squamous metaplasia of endometrial
epithelium (Figure S5B) was not observed in either Tsc2
cko or
Tsc1
cko uteri.
Synergistic effect of Pten deletion on Lkb1
cko phenotype
PJS patients can develop leiomyosarcomas [46] reinforcing the
importance of LKB1 in smooth muscle function and differentia-
tion. Also, deregulation of mTORC1 signaling and mutations in
various components of this pathway are commonly observed in
human smooth muscle tumors [47,48]. Paradoxically, loss of only
PTEN, an upstream regulator of the mTORC1 pathway, in
mesenchymal cells of the female reproductive tract is unable to
induce carcinogenesis in either stromal cells or the adjacent
epithelium [45,49,50]. Similarly, PTEN loss alone is unable to
initiate polycystic kidney disease or kidney cancer in mice [51].
However, Pten deletion does enhance polycystic kidney disease and
progression of the kidney cancer phenotype and decreases the
lifespan of Tsc1 mutant mice by over activating the mTORC1
pathway [51]. In this study we examined whether PTEN loss in
mesenchymal cells synergizes with LKB1 loss by developing
another mouse model with conditional deletion of both Lkb1 and
Pten genes (Lkb1
cko;Pten
cko). Grossly, the female reproductive tracts
of 5 week old Lkb1
cko;Pten
cko mice were enlarged and showed
abnormal growths compared with Lkb1
fl/fl;Pten
fl/fl controls
(Figure 7A and 7B). By 9 weeks, tumorous growths were observed
projecting through the vaginal opening of Lkb1
cko;Pten
cko mice
(N=8/10) but not in Lkb1
cko/+;Pten
cko or Lkb1
fl/fl;Pten
fl/fl mice
(Figure 7C). Dissection of Lkb1
cko;Pten
cko double mutant mice
revealed large tumorous growths in the uteri and in the cervix/
vagina region (N=20/20) (Figure 7D and 7E). Histological
examination of Lkb1
cko;Pten
cko uteri showed development of
endometrial intraepithelial neoplasia by 5 weeks (N=4/4), which
progressed to endometrial adenocarcinoma in 9 week old mice
(N=10/10) (Figure 7F–7M). In comparison, endometrial cancer
development usually required approximately 24 weeks to be
observed in Lkb1
cko mice. Colocalization of aSMA and CK8
showed that, similar to Lkb1
cko mice (Figure 5), expansion of
aSMA+ cells adjacent to CK8+ epithelial cells was also observed
in Lkb1
cko;Pten
cko mutant mice (Figure 7N–7Q). Examination of
oviducts from Lkb1
cko;Pten
cko mutants showed development of
oviductal cysts and adenomas akin to Lkb1
cko mice (Figure S6A
and S6B). However, oviductal abnormalities appeared much
earlier in Lkb1
cko;Pten
cko mutants (12 weeks) compared with Lkb1
cko
mice (18 weeks).
Human cervical cancer and PJS patients show alterations in
LKB1/mTORC1 signaling [10,18,52]. Even though Misr2-Cre
causes recombination in stromal cells of the cervix and upper
vagina (Figure S1), no tumor formation was observed in these
organs of Lkb1
cko, Tsc1
cko, and Tsc2
cko mice (N=5/each; data not
shown). However, loss of both LKB1 and PTEN initiated tumor
formation in cervices and vaginas of mutant animals (N=20/20)
(Figure S6C and S6D). Histological examination of the lower
reproductive tracts (endocervix, cervix and vagina) of 5 week old
mice showed expansion of the stromal compartment and
hyperplasia of the adjoining epithelial cells (Figure S6E and
S6F). By 10 weeks, hyperplasia and/or neoplasia of cervical and
vaginal squamous epithelial cells were observed in Lkb1
cko;Pten
cko
mice (N=20/20) (Figure S6H–S6J). No similar changes were
observed in Lkb1
fl/fl;Pten
fl/fl control mice (N=5) (Figure S6G).
Interestingly, massive expansion of mesenchymal cells or areas
with mesenchymal only features were also observed in all cervical
and vaginal tumors examined (Figure S6K).
Discussion
Mutations in LKB1 are frequently observed in PJS patients and
associated with development of gastrointestinal, colorectal, pan-
creatic, breast, and gynecological and gonadal cancers [5,53].
LKB1 inhibits mTORC1 activity through AMPK, and loss of
LKB1 is associated with increased mTORC1 activity in both
human and murine tumors [5,54,55]. The mechanisms controlled
by the LKB1 in reproduction and gynecological cancers have not
been thoroughly investigated. However, recent studies have
highlighted the importance of the genes involved in this signaling
pathway in germ cell and reproductive tract biology. Oocyte-
specific loss of TSC1 or TSC2 leads to premature ovarian failure
and infertility in mice [56]. The deletion of Lkb1 in the murine
uterine epithelium activates mTORC1 signaling and leads to the
development of endometrial cancer [9]. Recently, we showed that
conditional deletion of TSC1 in the female reproductive tract
initiates oviductal epithelial cell dysplasia and causes blockage of
embryo transport through the oviduct leading to infertility in mice
[57]. In this report we have shown that conditional deletion of
Lkb1, Tsc1, and Tsc2 in the mesenchymal cells leads to the
development of oviductal and uterine pathologies such as
endometrial cancer, indicating that dysregulated mTORC1
signaling downstream of LKB1 signaling plays an important role
in pathogenesis of the observed defects (Summarized in Table S1).
The activation of mTOR signaling by dysregulated LKB1 has
been associated with smooth muscle development and associated
pathologies [58]. For example, intestinal polyps in human PJS
patients and an Lkb1 heterozygous mouse model show upregula-
tion of the mTOR activity and expansion of smooth muscle
compartment [58]. The deletion of Lkb1 using smooth muscle-
specific cre mice affects smooth muscle cells and leads to
hyperplasia of adjoining epithelial cells, causing development of
polyps similar to those observed in human patients with PJS [11].
The upregulation of mTOR signaling is also observed in human
smooth muscle tumors of the uterus known as leiomyomas and
similar tumors were developed in Eker rat with defective TSC2
signaling confirming that the mTORC1 pathway plays an
important role in the pathogenesis of these tumors [48]. In
another example, the loss of TSC1 in cardiac smooth muscle cells
results in cardiac hypertrophy and death [59]. The increase in
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signaling and rapamycin treatment of these mice rescues the
phenotype and leads to prolonged survival [59]. In this study, we
showed that inhibition of mTORC1 signaling by rapamycin
significantly suppressed tumor burden in Lkb1 mutant mice
(Figure 6), further highlighting the contribution of dysregulated
mTORC1 signaling to development of Lkb1 mutant phenotype.
We show that mutation of stromal Lkb1 induces proliferation of
adjacent oviductal and uterine epithelium (Figure 1 and Figure 5)
accompanied by increased TGFb signaling (Figure 3 and Figure
Figure 6. Dysregulated mTORC1 activity in Lkb1 mutant mice. (A) Animal and uterine weight of Lkb1
cko mice (.7 month old mice) treated
with rapamycin or vehicle control. (B and C) Gross female reproductive tracts (arrow) of vehicle- and rapamycin-treated Lkb1
cko mice. pS6 IHC (D and
E) and histology (F and G) of Lkb1 mutant mice treated with vehicle or rapamycin. The black lines in panels D and E demarcate stromal (S) from
epithelial cells. Histology and CK8/aSMA staining of Tsc2
fl/fl (H and K), Tsc2
cko (I and L), and Tsc1
cko (J and M) uteri. Bars: 50 um.
doi:10.1371/journal.pgen.1002906.g006
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suppression and promotion [60]. Increased TGFb signaling is
associated with tumor promotion in pancreatic and breast cancer
models [61,62]. In contrast, loss of TGFb signaling leads to the
development of prostate and gastric carcinomas [34]. In the
intestine, loss of LKB1 in mesenchymal cells causes decreased
TGFb signaling, which is associated with polyp development,
suggesting that LKB1 signaling promotes TGFb signaling [11]. In
contrast, a recent study showed that LKB1 inhibits TGFb
signaling and promotes epithelial differentiation [32]. We suspect
that the role of TGFb in carcinogenesis is highly context and/or
tissue dependent [34].
Figure 7. Formation of highly aggressive endometrial adenocarcinoma in Lkb1
cko;Pten
cko mice. (A and B) Female reproductive tracts from
Lkb1
fl/fl;Pten
fl/fl and Lkb1
cko;Pten
cko mice. Arrowheads point to overgrowths. Arrows: Cervix and vagina. (C) Lkb1
cko;Pten
cko mice with abnormal growths
(arrowheads) projecting through their vaginas. (D and E) Uterine (Ut) and cervical/vaginal tumors (arrow) in double mutant mice. H&E sections of 5
week and 9 week old control (F, H, L)) and mutant (G, I, M) uteri. Colocalization of CK8 (green) and aSMA (red) in control (J, N and O) and double
mutant (K, P and Q) uteri. Ut: uterus. Bars: 50 um.
doi:10.1371/journal.pgen.1002906.g007
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human cervical cancer patients [10] and activation of mTORC1,
a downstream target of LKB1 signaling, has been observed in 54%
of human cervical adenocarcinoma patients [63]. Inhibition of
mTORC1 decreases proliferation and induces apoptosis in
cervical cancer cell lines [52]. These studies indicate the critical
role played by this pathway in cervical tumorigenesis. Human PJS
patients also develop malignant tumors in the endocervix known
as adenoma malignum [18]. However, tumor formation in the
cervix has not been reported in Lkb1 mutant mouse models [9,19].
Because these previous studies mainly focused on the role of LKB1
signaling in epithelial cells, the contribution of dysregulated
stromal LKB1 signaling in cervical carcinogenesis has been
unappreciated. Examination of the lower female reproductive
tracts (cervix and vagina) collected from Lkb1, Tsc1, and Tsc2
mutant mice showed no abnormal growth in these organs.
However, cervical/vaginal epithelial hyperplasia and neoplasia
were observed in Lkb1
cko;Pten
cko mice (Figure 7), indicating that loss
or alterations in the activity of another tumor suppressor in
combination with defective LKB1 activity is required for cervical
carcinogenesis.
We have shown that defective LKB1/TSC1/TSC2/mTORC1
signaling in mesenchymal cells is sufficient to cause epithelial
hyperplasia, adenoma and paratubal cysts in oviducts, and uterine
endometrial cancer in mice. A significant proportion of PJS
patients harbor mutations that encompass whole or partial LKB1
gene deletions [64], and comparative analyses of human
oviductal/ovarian adenomas revealed similar changes in the
stromal population, making this mouse model appropriate for
studying this disease. Future studies will investigate human
oviductal or ovarian adenomas and endometrial carcinoma
associated mesenchymal cells for genetic mutations or alterations
in this signaling pathway with the expectation of strong support for
treating PJS patients with therapies targeting mTORC1, such as
rapamycin and its analogs.
Materials and Methods
Mouse genetics and husbandry
Allprotocolsinvolvinganimalexperimentationareincompliance
with the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use
Committee at Massachusetts General Hospital. Mice used in this
study were housed under standard animal housing conditions and
maintained on a mixed genetic background (C57BL/6;129/SvEv).
The following mice strains: Amhr2
tm3(cre)Bhr (also known as Misr2-Cre,
obtained from Dr. Richard Behringer, [16]), and Stk11
tm1Rdp
(Lkb1
fl/fl, [19]), Tsc1
fl/fl [65], Tsc2
fl/fl [66], Pten
tm1Hwu [67] were
mated to produce Amhr2
tm3(cre)Bhr/+;Stk11
D/D, Amhr2
tm3(cre)Bhr/
+;Tsc2
D/D, Amhr2
tm3(cre)Bhr/+;Tsc1
D/D, Amhr2
tm3(cre)Bhr/+;Pten
D/D and
Amhr2
tm3(cre)Bhr/+;Stk11
D/D; Pten
D/D hereafter referred to as Lkb1
cko,
Tsc2
cko, Tsc1
cko,a n dLkb1
ckoPten
cko respectively. Whenever possible,
littermate control mice were used in all experiments. Misr2-
Cre;Rosa26Lacz
fl/fl reporter mice were generated as previously
described [4]. Tail biopsies were used to perform genotyping using
standard PCRprotocolsasdescribed forMisr2-Cre [22] and withthe
following primers and conditions to detect wt and flox alleles of Lkb1
59-GGG CTT CCA CCT GGT GCC AGC CTG T, 59-GAT
GGA GAA CCT CTT GGC CGG CTC A-39 and 59-GAG ATG
GGTACCAGGAGTTGG GGC T and35 cyclesof94 C 30 sec,
65 C 1 min, 72 C 1 min. PCR conditions for Tsc1, Tsc2, and Pten
alleles are previously described in detail [45,57,66]. Gross pictures
of weretaken using a NikonSMZ1500 microscope with an attached
Spot camera (Diagnostic Instruments, Sterling Heights, MI) or with
a Nikon D60 digital camera and macro lens. Bromophenol blue dye
injections were performed as previously described [20]. Briefly,
0.25% bromophenol blue solution was injected into the lumen of
oviducts at the uterotubal junction or lumen of the uterus in adult
control and Lkb1
cko mutant oviducts (N=3/each). The oviducts
were grossly examined under microscope.
Lkb1
cko mutant mice (.7 month old, N=3/group) were given
either rapamycin (250 ug by oral gavage, Rapamune, Wyeth, PA)
or an equivalent volume of vehicle control (The American
Lecithin company, Oxford, CT) as previously described in [45]
for five days per week for three weeks. After the treatment period,
animals were euthanized and tissues were collected for further
analyses.
Histology, immunohistochemistry (IHC),
immunofluorescence (IF), b-galactosidase staining
The female reproductive tracts from control and mutant
animals were collected at different stages of development. For
histological examination, tissues were fixed in 4% paraformalde-
hyde for 10–12 h at 4uC, processed as previously described [4],
and examined by an experienced human oviductal pathologist.
Paraffin embedded tissue sections of human oviductal/ovarian
adenomas were obtained from Department of Pathology, Brigham
and Women’s Hospital using Institutional Review Board-approved
protocols. Detailed methods for IHC and IF are described
elsewhere [4,68]. Tumors were graded using the FIGO staging
system. The primary and secondary antibodies used in this study
are: b-catenin (BD Transduction Laboratories, San Jose, CA); E-
cadherin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA);
aSMA (Sigma, St. Louis, MO); TJP-1/ZO-1 (Developmental
Studies Hybridoma Bank, Iowa City, IA); phospho-riboprotein S6,
phospho-SMAD1 (Ser463/465)/5(Ser463/465)/8 (Ser426/428),
phospho-mTOR (Cell Signaling Technology, Danvers, MA);
phospho-SMAD2, phospho-Histone H3 (Millipore, Billerica,
MA); cytokeratin, desmin (Neomarkers, Fremont, CA); cytokeratin
8 (Developmental studies hybridoma bank, IA), PAX2, AlexaFluor
second antibodies (Invitrogen, Carlsbad, CA); and biotinylated
donkey antimouse or antirabbit F(ab)2 fragments (Jackson
ImmunoResearch, West Grove, PA). Photos were taken with a
Nikon TE2000S with an attached Spot camera (Diagnostic
Instruments) or Nikon Eclipse Ni fitted with Nikon DSF12/DS-
Q1MC camera. For measurements, images were analyzed from
minimum of three different animals per group using Nikon NIS
elements imaging or ImageJ (National Institute of Health,
Bethesda, MD) software.
For b-galactosidase staining, female reproductive tract from
Misr2-Cre;Rosa26Lacz
fl/+ and Rosa26Lacz
fl/+ reporter mice were
collected at 5–6 weeks of postnatal. Tissues were fixed for 1 h at
4uC then washed and stained in X-gal solution at room
temperature for 3–4 h. After a quick rinse with PBS, tissues were
processed for histology. Masson’s Trichrome staining was
performed using a kit (Sigma).
Western blot analyses
Oviducts (N=3/each) from Lkb1 control and mutant animals
were collected and protein extracts were prepared using RIPA
buffer as described in [4]. Protein concentration was determined
using the Bradford assay and equal amounts protein was loaded in
gels. The following antibodies are used: S6, pS6, pRAPTOR, 4E-
BP1, p4EBP1 (Cell Signaling Technology); b-catenin (Sigma);
pSMAD2 (Millipore); b-actin (Neomarkers). Western blot films
were scanned and bands were analyzed by pixel density for
statistical analyses.
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Statistical analyses were performed using Prism software
(GraphPad software, La Jolla, CA). The Student t test was used
to calculate differences between the groups (N$3/group), and
p values#0.05 were considered statistically significant.
Supporting Information
Figure S1 Conditional deletion of LKB1 in oviductal mesen-
chymal cells using Misr2-Cre. (A–C) Misr2-Cre driven b-
galactosidase expression (Misr2-Cre;Rosa26LacZ
flox/flox) in oviductal,
cervical and vaginal mesenchymal cells (S) but not in epithelial
cells (Epi). Genomic PCR confirms recombination of Lkb1 (D) and
Tsc2 (E) alleles in Misr2-Cre expressing organs (oviduct, ovary and
uterus). Bars: 50 um.
(TIF)
Figure S2 Localization of cytoskeleton and epithelial proteins in
mutant oviducts. 5 week old oviducts from controls (N=3) and
Lkb1 mutants (N=3) were examined for expression of cytokeratin
(A and B), b-catenin (C and D), E-cadherin (E and F), and Tight
Junction Protein 1 (TJP1/ZO-1) (G and H). Arrowheads in panel
B, D, F and H point to the epithelial cells displaced into the
oviductal lumen. Colocalization of PAX2 (green) and aSMA (red)
in control oviducts (I and K). PAX2 expression was absent in
fimbrial epithelial cells (asterisk) but present in the rest of the
oviductal epithelial cells. PAX2 expression in mutant oviducts (J
and L) was similar to controls. O: ovary, Ovi: oviduct, Ut: uterus
Bars: 50 um.
(TIF)
Figure S3 Histological analyses of TSC2
cko mutant oviducts. 6
week old oviducts from control (A and C) and Tsc2 mutant (B and
D) mice. Asterisks (*) in C and D mark the fimbriae/distal
segments of the oviducts. Bars: 50 um or as otherwise mentioned.
(TIF)
Figure S4 Comparison of uteri with deletion of LKB1 in the
epithelium combined with Lkb1
cko. Gross female reproductive
tracts from Lkb1
fl/fl, Lkb1
cko, and Lkb1
cko/- mice (A–C). Arrows in
panel in A to C point to the uterus. Increased expression of aSMA
(D–F), pH 3 (G–I), pmTOR (J–L), and pS6 (M–O) in mesenchy-
mal cells of 9 week old Lkb1
cko uteri compared to controls.
Columns represent the mean values for n as indicated. Error bars
represent SEM. An asterisk indicates that expression in the mutant
mice was significantly higher. White solid line outlines the area
used for the analyses of aSMA- or pH 3-positive cells or brightness
of pmTOR and pS6 staining. White dotted line outlines the
stromal compartment or epithelial cells, which were excluded from
the analyses. Co-localization of pSMAD2 and aSMA by
immunofluorescence in control (P) and Lkb1 mutant (Q) uteri. E:
Uterine epithelial cells. Bars: 50 um.
(TIF)
Figure S5 Rapamycin-treated oviducts and metaplasia of the
uterine epithelium in adult Lkb1
cko. (A) The oviducts of Lkb1
cko mice
treated with rapamycin (a) have fewer and smaller cysts compared
to vehicle-treated controls (b). (B) Squamous epithelial cells were
observed by H&E in Lkb1 mutant uteri (b, c, e and f) but not in
controls (a and d) or Tsc1/Tsc2 (g and h) mutants. Arrows:
squamous epithelium, Arrowheads: columnar epithelium. Bars:
50 um.
(TIF)
Figure S6 Accelerated tumorigenesis in Lkb1
cko;Pten
cko mice.
H&E analyses of (A) Ovary, oviduct, and uterus from 12 week
old Lkb1
fl/fl;Pten
fl/fl mice and (B) oviductal cysts (arrow) and
adenoma in Lkb1
cko;Pten
cko mutant mice. Lower female reproduc-
tive tract (endocervix, cervix and vagina) from 5 week old control
(C and E) and mutant (D and F) mice. Cervix and vagina of adult
control (G) and mutant (H and I) mice. Arrow in panel H and I
mark focal stromal hyperplasia. Cervical hyperplasia and neopla-
sia (arrows) in Lkb1
cko;Pten
cko mice (J). Black dotted line demarcates
the cervix from the uterus. Arrowhead marks focal mesenchymal
cell hyperplasia. Tumors mainly consist of mesenchymal cells
present in the cervix/vagina of mutant mice (K). Inset is a higher
magnification image of boxed area in K. S, stroma; Ut, uterus
Bars: 50 um unless otherwise indicated.
(TIF)
Table S1 Phenotype frequency.
(DOC)
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